Drug intelligence / Profile preview

anti-CLDN6 bispecific antibody

Development stage
Unknown
Lead developer
Context Therapeutics
Modality
Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

**Anti-CLDN6 bispecific antibody** is a non-specific descriptor that can refer to multiple investigational antineoplastic biologics directed against **claudin 6**, most notably **CLDN6 x CD3 T-cell-engaging bispecific antibodies** such as CTIM-76, BNT142, and AMG 794. These agents are being developed for **CLDN6-positive solid tumors** including ovarian, endometrial, and testicular cancers. Their intended mechanism is to bind **CLDN6** on tumor cells and **CD3** on T cells, thereby redirecting T-cell cytotoxicity toward CLDN6-expressing cancer cells. Because the query does not identify a single molecule, developer, construct format, and development stage cannot be assigned to one unique drug with confidence.

Other names
CLDN6 bispecific antibodyCLDN-6 bispecific antibodyCLDN 6 bispecific antibodyCLDN6-directed T cell-engaging bispecific antibodyCLDN-6-directed T cell-engaging bispecific antibodyCLDN 6-directed T cell-engaging bispecific antibodyCLDN6 x CD3 bispecific antibodyCLDN-6 x CD3 bispecific antibodyCLDN 6 x CD3 bispecific antibodyanti-CD3 anti-CLDN6 bispecific antibodyanti-CD-3 anti-CLDN6 bispecific antibodyanti-CD 3 anti-CLDN6 bispecific antibodyclaudin-6 bispecific antibodyclaudin6 bispecific antibodyclaudin 6 bispecific antibody
02

Targets

CD3 (T-cell surface glycoprotein CD3)CLDN6 (Claudin-6)

Beyond the preview

Go deeper on anti-CLDN6 bispecific antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CLDN6 bispecific antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call